fgf-401
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 29, 2014 (NCT02325739)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Fibroblast growth factor receptor 4INHIBITOR
FGFR4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N- Mol. weight
- 506.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3908979 ↗
- ChEMBLCHEMBL3545293 ↗
Also known as
- fgf401
- fgf401
- fgf401
- fgf-401
- fgf-401
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02325739 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2014 | Novartis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1